Table 2. Clinico-pathologic variables and DFNA5 methylation in primary breast cancer.
| DFNA5 TaqMan methylaiton analysis | ||||
|---|---|---|---|---|
| M+n = 12 | M−n = 14 | P value | UC | |
| Age (years) | 54.5 ± 10.7 | 52.9 ± 27.2 | ||
| Differentiation | 1.000 | 2 | ||
| Well and moderately | 8 | 8 | ||
| Poorly | 4 | 4 | ||
| Lymph node metastasis | 0.001* | 5 | ||
| Absence | 2 | 11 | ||
| Presence | 7 | 1 | ||
| Lymphatic permeation | 0.305 | 3 | ||
| Absence | 4 | 6 | ||
| Presence | 8 | 5 | ||
| Vacsular permeation | 0.315 | 5 | ||
| Absence | 9 | 10 | ||
| Presence | 3 | 1 | ||
| Estrogen receptor | 0.219 | |||
| Absence | 8 | 5 | ||
| Presence | 4 | 7 | ||
| Progesteron receptor | 0.673 | |||
| Absence | 8 | 7 | ||
| Presence | 4 | 5 | ||
| Tumor size | 0.750 | |||
| <2 cm | 2 | 3 | ||
| >2 cm | 10 | 11 | ||
| TNM staging | 0.208 | |||
| Stage I and II | 9 | 13 | ||
| Stage III and IV | 3 | 1 | ||
Note. Some patients did not have clinical information.
#UC = number of patients that the clinical variables indicated were uncharaterized.
Age was shown as means ± SD in each group with (M+) or without methylation (M−).
Chi-square test for age was not performed in this study.
Methylation positivity (M+) and negativity (M−) were based on TaqMeth V at a cutoff value 0.81. M+, TaqMeth V over 0.81; M−, TaqMeth V below 0.81.
LNM determined by surgeons.
P value was calculated from the Chi-square test.
*
Significant (P < 0.05).